Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q1 EPS of $0.35, $0.10 better than the analyst estimate of $0.25. Revenue for the quarter came in at $16 million versus the consensus estimate of $13.63 million.

For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.